Literature DB >> 30948275

Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge.

Fabrice Jardin1.   

Abstract

Entities:  

Year:  2019        PMID： 30948275     DOI： 10.1016/S1470-2045(19)30021-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Authors:  Arushi Khurana; Raphael Mwangi; Grzegorz S Nowakowski; Thomas M Habermann; Stephen M Ansell; Betsy R LaPlant; Brian K Link; James R Cerhan; Matthew J Maurer; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2021-02-02       Impact factor: 44.544

2.  Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.

Authors:  S Jemaa; J N Paulson; M Hutchings; L Kostakoglu; J Trotman; S Tracy; A de Crespigny; R A D Carano; T C El-Galaly; T G Nielsen; T Bengtsson
Journal:  Cancer Imaging       Date:  2022-08-12       Impact factor: 5.605

3.  Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma.

Authors:  Qiangqiang Zhao; Duanfeng Jiang; Xiaoying Sun; Qiuyu Mo; Shaobin Chen; Wansong Chen; Rong Gui; Xianjun Ma
Journal:  J Nanobiotechnology       Date:  2021-06-13       Impact factor: 10.435

Review 4.  Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.

Authors:  Jennifer L Crombie; Philippe Armand
Journal:  J Clin Oncol       Date:  2020-08-19       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.